NSAIDs for analgesia in the era of COVID-19.
Daniel L HerzbergHarry P SukumaranEugene R ViscusiPublished in: Regional anesthesia and pain medicine (2020)
Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one's likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need.
Keyphrases
- anti inflammatory drugs
- coronavirus disease
- end stage renal disease
- sars cov
- pain management
- ejection fraction
- chronic pain
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- electronic health record
- depressive symptoms
- big data
- postoperative pain
- spinal cord
- deep learning